Mohamed Mutalib1, Osvaldo Borrelli2, Sarah Blackstock2, Fevronia Kiparissi2, Mamoun Elawad2, Neil Shah2, Keith Lindley2. 1. Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Sick Children NHS Foundation Trust, United Kingdom. Electronic address: mohamed.mutalib@gosh.nhs.uk. 2. Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Sick Children NHS Foundation Trust, United Kingdom.
Abstract
BACKGROUND: Management of refractory inflammatory bowel disease (IBD) in children is challenging and once response to conventional medical therapy deviates from the expected, options are often limited. Sirolimus is commonly used in post-transplantation management and is used sparsely as rescue therapy in refractory Crohn's disease. In the present study, we report the efficacy of sirolimus as an adjuvant immunosuppressive therapy in a retrospective case review of a selected group of IBD children who were refractory to the conventional treatments. METHODS: Medical records of children with refractory IBD unresponsive to conventional therapy and started on sirolimus between 2006 and 2012 were retrospectively reviewed. Clinical response, through Pediatric Ulcerative Colitis Activity Index (PUCAI) and Pediatric Crohn's Disease Activity Index (PCDAI), as well as intestinal inflammation, through specific histological scores, was evaluated. RESULTS: The records of 14 patients were analyzed. Eleven of them had ulcerative colitis (UC) and 3 Crohn's disease (CD); mean age at diagnosis was 9.1 years (standard deviation 3.8). Of UC patients, 5 (45%) achieved clinical remission and 2 (18%) showed clinical response. All CD patients went into clinical remission. Mucosal healing was achieved by 5 children (45%) with UC and 2 (67%) with CD patients. One child with ulcerative colitis was weaned off adalimumab, while 2 children with CD were weaned off prednisolone and methotrexate successfully. CONCLUSION: Our data provide evidence that sirolimus seems to be effective as rescue therapy in a subgroup of children with severe IBD refractory to conventional therapies by inducing both clinical remission and mucosal healing.
BACKGROUND: Management of refractory inflammatory bowel disease (IBD) in children is challenging and once response to conventional medical therapy deviates from the expected, options are often limited. Sirolimus is commonly used in post-transplantation management and is used sparsely as rescue therapy in refractory Crohn's disease. In the present study, we report the efficacy of sirolimus as an adjuvant immunosuppressive therapy in a retrospective case review of a selected group of IBD children who were refractory to the conventional treatments. METHODS: Medical records of children with refractory IBD unresponsive to conventional therapy and started on sirolimus between 2006 and 2012 were retrospectively reviewed. Clinical response, through Pediatric Ulcerative Colitis Activity Index (PUCAI) and Pediatric Crohn's Disease Activity Index (PCDAI), as well as intestinal inflammation, through specific histological scores, was evaluated. RESULTS: The records of 14 patients were analyzed. Eleven of them had ulcerative colitis (UC) and 3 Crohn's disease (CD); mean age at diagnosis was 9.1 years (standard deviation 3.8). Of UC patients, 5 (45%) achieved clinical remission and 2 (18%) showed clinical response. All CDpatients went into clinical remission. Mucosal healing was achieved by 5 children (45%) with UC and 2 (67%) with CDpatients. One child with ulcerative colitis was weaned off adalimumab, while 2 children with CD were weaned off prednisolone and methotrexate successfully. CONCLUSION: Our data provide evidence that sirolimus seems to be effective as rescue therapy in a subgroup of children with severe IBD refractory to conventional therapies by inducing both clinical remission and mucosal healing.
Authors: Larissa S Celiberto; Franziska A Graef; Genelle R Healey; Else S Bosman; Kevan Jacobson; Laura M Sly; Bruce A Vallance Journal: Immunology Date: 2018-05-16 Impact factor: 7.397
Authors: Bernard Khor; Kara L Conway; Abdifatah S Omar; Moshe Biton; Adam L Haber; Noga Rogel; Leigh A Baxt; Jakob Begun; Petric Kuballa; John D Gagnon; Kara G Lassen; Aviv Regev; Ramnik J Xavier Journal: J Immunol Date: 2019-08-26 Impact factor: 5.422
Authors: Sidrah Khan; Heather L Mentrup; Elizabeth A Novak; Vei Shaun Siow; Qian Wang; Erin C Crawford; Corinne Schneider; Thomas E Comerford; Brian Firek; Matt B Rogers; Patricia Loughran; Michael J Morowitz; Kevin P Mollen Journal: FASEB J Date: 2022-05 Impact factor: 5.834
Authors: Wiebe Vanhove; Kris Nys; Ingrid Arijs; Isabelle Cleynen; Manuel Noben; Sebastiaan De Schepper; Gert Van Assche; Marc Ferrante; Séverine Vermeire Journal: J Crohns Colitis Date: 2018-01-24 Impact factor: 9.071